Dissecting the role of DNA Ligase 1 in Huntington's disease
剖析 DNA 连接酶 1 在亨廷顿舞蹈病中的作用
基本信息
- 批准号:10733111
- 负责人:
- 金额:$ 63.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-25 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AgeAge of OnsetAllelesBindingBiochemicalBiological AssayBiological ProcessBiologyCAG repeatCRISPR-mediated transcriptional activationCellsCellular StressCessation of lifeChromosomesClinicalComplexDNA DamageDNA LigasesDNA LigationDNA RepairDNA Sequence AlterationDataDiseaseFamilyGene ModifiedGene MutationGenesGenetic RecombinationGenetic TranscriptionGenetic VariationHaplotypesHealth Care CostsHistologicHomologous GeneHumanHuman GeneticsHuntington DiseaseHuntington geneInheritedKnock-in MouseLengthLigaseLong-Term CareMass Spectrum AnalysisModelingModificationMolecularMusMutationNeurobehavioral ManifestationsNeurodegenerative DisordersNeuronal DifferentiationNeuronsNuclearOnset of illnessPathogenesisPathogenicityPathologyPatientsPhenotypeProcessProteinsResearchRoleSeriesStructureSubstrate SpecificityTestingTherapeuticTherapeutic InterventionTimeTissuesToxic effectUp-RegulationVariantX-Ray Crystallographybrain tissuecell free DNAeffective therapyemotional symptomexperimental studyfunctional outcomesgene discoverygenetic manipulationgenome wide association studyinduced pluripotent stem cellinsightmotor symptommouse modelmultiplex assaymutantnerve stem cellnew therapeutic targetnovelprotein purificationrepairedresponsesealtargeted treatmenttranscriptome
项目摘要
Huntington’s disease (HD) is a devastating and fatal neurodegenerative disorder caused by the expansion of a
polymorphic CAG repeat in the HTT gene. Although the underlying genetic mutation was discovered over 25
years ago, there is still no cure or effective treatment despite extensive efforts. The CAG repeat mutation
undergoes time- and CAG length-dependent somatic expansion and recent genome-wide association studies
(GWAS) support somatic CAG expansion as the first step of the pathogenic process, required to elicit cellular
toxicity and ultimately clinical disease. GWAS identified several genes involved in DNA repair as modifiers of
age of onset, among which is LIG1, encoding DNA ligase 1. The biological function of DNA ligase 1 implicates
it in somatic CAG expansion, however this gene may also alter processes that impact on cellular toxicity.
Overall, the mechanistic underpinnings of disease modification remain obscure. Independent LIG1 modifier
chromosomes can be distinguished in the human genetic data: one, tagged by a predicted deleterious SNP
encoding a K854N substitution, is onset-delaying, while another is associated with increased LIG1 expression
and is onset-hastening. In this study, we will perform experiments to test hypotheses rooted in human genetic
data to understand the functional consequences of these LIG1 modifier effects. In Aim 1 we will use a knock-in
mouse model of HD to test the impact of the K>N substitution mutation introduced into the mouse Lig1 gene,
and to test the impact of Lig1 upregulation, on somatic CAG expansion and phenotypic expression. In Aim 2
we will use HD patient-derived and isogenic neuronal progenitor cells and neurons harboring LIG1 modifier
alleles to identify their cellular and molecular consequences and to test their impacts on phenotypes elicited by
the HTT mutation. In Aim 3 we will perform biochemical, structural and functional analyses of the LIG1 K845N
variant. Together, these experiments will provide novel insight into mechanisms by which genetic variation in
LIG1 modifies disease in patients, ultimately revealing therapeutic avenues that can be pursued for disease-
modifying treatments.
亨廷顿氏病(HD)是一种由灾难性和致命的神经退行性疾病。
在25岁以上发现了潜在的基因突变中的多态CAG CAG重复体
尽管如此,尽管如此,但仍然没有治疗或有效的治疗方法
经过时间和CAG长度依赖性的体细胞扩张和最新的全基因组关联研究
(GWAS)支持躯体CAG扩展作为致病过程的第一步,以引起细胞
毒性和最终临床疾病。
发病年龄,其中是LIG1,编码DNA连接酶1。DNA连接酶1的生物学功能与
它在体细胞CAG扩展中,但是该基因也可能处理影响细胞毒性的基因。
总体而言,疾病修饰的机械基础仍然晦涩难懂
可以在人类遗传数据中区分染色体:一个由预测的有害SNP标记
编码K854N替换是开始延迟的,而另一个则与Lig1表达增加有关
并且是为了发作,在这项研究中,我们将进行实验以测试植根于人文的假设
了解这些Lig1修饰符效应的功能构造。
HD的小鼠模型测试引入小鼠Lig1基因的K> n变量突变的影响,
并测试LIG1上调的影响,对AIM 2中的体细胞cag扩展和表型表达
我们将使用HD患者衍生的和同基因神经元细胞和带有Lig1修饰符的Neurbon
等位基因以鉴定其细胞和分子后果,并测试对由表型产生的影响
AIM 3中的HTT突变我们将进行LIG1 K845N的生化,结构和功能分析
变体。
Lig1修改患者的疾病,最终启发可用于疾病的治疗途径
修改治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ihn Sik Seong其他文献
Ihn Sik Seong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ihn Sik Seong', 18)}}的其他基金
An alternative isoform of RRM2B as a genetic modifier in Huntington's disease
RRM2B 的另一种亚型作为亨廷顿病的遗传修饰剂
- 批准号:
10405581 - 财政年份:2020
- 资助金额:
$ 63.07万 - 项目类别:
An Alternative Isoform of RRM2B as a Genetic Modifier in Huntington's Disease
RRM2B 的替代亚型作为亨廷顿病的遗传修饰剂
- 批准号:
10621765 - 财政年份:2020
- 资助金额:
$ 63.07万 - 项目类别:
Effects of PolyQ Expansion on Full-length Huntingtin Protein in HD
PolyQ 扩增对 HD 中全长亨廷顿蛋白的影响
- 批准号:
8343248 - 财政年份:2012
- 资助金额:
$ 63.07万 - 项目类别:
Effects of PolyQ Expansion on Full-length Huntingtin Protein in HD
PolyQ 扩增对 HD 中全长亨廷顿蛋白的影响
- 批准号:
8659524 - 财政年份:2012
- 资助金额:
$ 63.07万 - 项目类别:
Effects of PolyQ Expansion on Full-length Huntingtin Protein in HD
PolyQ 扩增对 HD 中全长亨廷顿蛋白的影响
- 批准号:
8487470 - 财政年份:2012
- 资助金额:
$ 63.07万 - 项目类别:
Effects of PolyQ Expansion on Full-length Huntingtin Protein in HD
PolyQ 扩增对 HD 中全长亨廷顿蛋白的影响
- 批准号:
8842213 - 财政年份:2012
- 资助金额:
$ 63.07万 - 项目类别:
相似国自然基金
PLAAT3降低介导线粒体降解异常在年龄相关性白内障发病中的作用及机制
- 批准号:82301190
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
晶状体mtDNA氧化损伤修复与线粒体自噬的空间差异及其调控干预在年龄相关性白内障发病中的作用
- 批准号:82171038
- 批准年份:2021
- 资助金额:54 万元
- 项目类别:面上项目
FoxO3a通路抑制在年龄相关性白内障发病机制中的调控作用
- 批准号:82070942
- 批准年份:2020
- 资助金额:57 万元
- 项目类别:面上项目
ODRP泛素化经LECs外泌体释放和自噬降解调控年龄相关性白内障的发病
- 批准号:81974129
- 批准年份:2019
- 资助金额:57 万元
- 项目类别:面上项目
肠道微生态参与年龄相关性黄斑变性的发病机制及固本清目方的干预作用
- 批准号:81973912
- 批准年份:2019
- 资助金额:55 万元
- 项目类别:面上项目
相似海外基金
Neuronal ABCA7 loss of function and Alzheimer’s disease
神经元 ABCA7 功能丧失与阿尔茨海默病
- 批准号:
10629715 - 财政年份:2023
- 资助金额:
$ 63.07万 - 项目类别:
SPOP modifies neurodegenerative proteinopathy in Alzheimer’s Disease.
SPOP 可以改善阿尔茨海默病中的神经退行性蛋白病。
- 批准号:
10675938 - 财政年份:2023
- 资助金额:
$ 63.07万 - 项目类别:
HMGB1 in EB-Associated Squamous Cell Carcinoma
EB 相关鳞状细胞癌中的 HMGB1
- 批准号:
10676346 - 财政年份:2023
- 资助金额:
$ 63.07万 - 项目类别:
Upregulation of progranulin in a human iPSC-derived neurovascular model of GRN-associated Frontotemporal Dementia
GRN 相关额颞叶痴呆的人 iPSC 衍生神经血管模型中颗粒体蛋白前体的上调
- 批准号:
10789724 - 财政年份:2023
- 资助金额:
$ 63.07万 - 项目类别:
Regulation of diverse microglial phenotypes in neurodegeneration
神经退行性变中不同小胶质细胞表型的调节
- 批准号:
10901024 - 财政年份:2023
- 资助金额:
$ 63.07万 - 项目类别: